Human immunodeficiency virus (HIV), one of most serious public health challenges in the world, has already affected approximately 37.6 million people across the globe in 2020 and new infections in 2020 are estimated to be 1.5 million. Bictegravir/ Emtricitabine/ tenofovir (BIC/TAF/FTC) is a fixed-dose combination tablet consisting of an integrase inhibitor and two nucleoside reverse transcriptase inhibitors for the treatment of HIV infection. This HIV medication was approved by the United States Food and Drug Administration (USFDA) in 2018 due to the excellent efficacy outcomes in clinical trials. Real-world safety data of BIC/TAF/FTC was presented at the 18th European AIDS Conference in 2021 and summarised below.
Tag Archive for: adverse events
https://ftp.medi-paper.com/wp-content/uploads/2021/11/Gender-related-differences-in-safety.jpg 1024 1917 Connie TANG https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Connie TANG2021-11-03 14:49:542021-11-04 18:56:58Gender-related differences in safety after switching to BIC/TAF/FTC